DEFA14A: Veeva Systems Addresses Director Overboarding Concerns Ahead of 2025 Annual Meeting

Veeva Systems provides supplemental information regarding director nominee Paul Sekhri's board commitments to alleviate investor concerns about him being 'overboarded'.

Summary

• Veeva Systems Inc. has released supplemental materials to its proxy statement for the 2025 Annual Meeting of Shareholders, scheduled for June 18, 2025.
• The supplement addresses concerns about director nominee Paul Sekhri potentially being 'overboarded' due to his multiple board commitments.
• Mr. Sekhri is the CEO and a board member of vTv Therapeutics Inc. and also serves on the board of Compugen Ltd.
• Compugen announced on May 13, 2025, that Mr. Sekhri will step down from its board in September 2025.
• Veeva believes this change should address investor concerns about Mr. Sekhri's public company board commitments.
• The Board of Directors strongly encourages shareholders to vote FOR Mr. Sekhri on Proposal One, emphasizing his expertise and value to the Board.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is proactively addressing a potential governance issue and expressing confidence in a key director nominee.

Positives

• Veeva is proactively addressing investor concerns regarding director nominee Paul Sekhri.
• Paul Sekhri's stepping down from the Compugen board is expected to resolve 'overboarding' issues.
• The Board expresses strong confidence in Mr. Sekhri's contributions and encourages shareholders to support his election.

Risks

• There is a risk that some investors may still consider Mr. Sekhri to be 'overboarded' despite his planned departure from Compugen's board.
• Failure to elect Mr. Sekhri could potentially disrupt the Board's operations and strategic direction.

Future Outlook

The document focuses on the election of directors at the upcoming annual meeting and does not contain forward-looking financial statements.

Management Comments

• The Board strongly encourages you to vote FOR Mr. Sekhri on Proposal One.
• We believe that Mr. Sekhri has been, and will continue to be, an effective and engaged director who provides important perspective and immense value to our Board, in particular due to his expertise and experience in the life sciences industry.

Industry Context

In the life sciences industry, having directors with deep expertise is crucial for guiding companies through complex regulatory landscapes and market dynamics; Veeva's emphasis on Mr. Sekhri's experience reflects this need.

Comparison to Industry Standards

• Corporate governance guidelines often flag directors serving on an excessive number of boards, as it can impact their ability to dedicate sufficient time and attention to each company.
• Many institutional investors have specific policies regarding 'overboarding', which can lead to votes against director nominees.
• Companies like Veeva must proactively address these concerns to maintain investor confidence and ensure smooth board operations.

Stakeholder Impact

• Shareholders are directly impacted by the election of directors and the composition of the Board.
• The Board's effectiveness influences the company's strategic direction and overall performance, affecting all stakeholders.

Next Steps

• Shareholders will vote on the election of directors at the 2025 Annual Meeting on June 18, 2025.
• Mr. Sekhri will step down from the board of Compugen Ltd. in September 2025.

Key Dates

Keywords

Veeva Systems, Proxy Statement, Director Election, Paul Sekhri, Board Commitments, Overboarded, Annual Meeting, Compugen, vTv Therapeutics, Shareholders